897-899
Editorial
What is the true risk of a pharmacokinetic drug–drug interaction?
Uwe Fuhr
901-908
Clinical Trial
Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity
J.-C. Wasmuth, I. Lambertz, E. Voigt, M. Vogel and C. Hoffmann, et al.
909-912
Debate Article
An analysis of the clinical development of drugs in Norway for the years 2000 and 2004: the influence of the pharmaceutical industry
Finn O. Winther, Ola P. Hole and Sigurd Nitter-Hauge
913-916
Pharmacodynamics
Interaction between a commercially available St. John’s wort product (Movina) and atorvastatin in patients with hypercholesterolemia
L. Andrén, Å Andreasson and R. Eggertsen
917-925
Pharmacogenetics
Possible role of MDR1 two-locus genotypes for young-age onset ulcerative colitis but not Crohn’s disease
T. Fiedler, C. Büning, W. Reuter, G. Pitre and E. Gentz, et al.
927-933
Pharmacogenetics
Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyltransferase 2
Ryuji Kubota, Masako Ohno, Tomoko Hasunuma, Hajime Iijima and Junichi Azuma
935-940
Pharmacokinetics and Disposition
Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults
Nils von Hentig, Brenda Dauer, Annette Haberl, Stefan Klauke and Thomas Lutz, et al.
941-949
Pharmacokinetics and Disposition
Voriconazole and fluconazole increase the exposure to oral diazepam
Teijo I. Saari, Kari Laine, Leif Bertilsson, Pertti J. Neuvonen and Klaus T. Olkkola
951-957
Pharmacokinetics and Disposition
Gender-associated differences in pharmacokinetics and anti-arrhythmic effects of flecainide in Japanese patients with supraventricular tachyarrhythmia
Kosuke Doki, Masato Homma, Keisuke Kuga, Kazutaka Aonuma and Satoshi Sakai, et al.
959-971
Pharmacoepidemiology and Prescription
Digoxin and mortality in atrial fibrillation: a prospective cohort study
Pär Hallberg, Johan Lindbäck, Bertil Lindahl, Ulf Stenestrand and Håkan Melhus, et al.
973-978
Pharmacoepidemiology and Prescription
Adverse events of blood-pressure-lowering drugs: evidence of high incidence in a clinical setting
Carla B.C. Gonçalves, Leila B. Moreira, Miguel Gus and Flávio D. Fuchs
979-980
Letter to the Editors
Open AccessPatient-reporting of side effects may provide an important source of information in clinical practice
Juliet M. Foster, Thys van der Molen and Lolkje de Jong - van den Berg
981
Letter to the Editors
Reply to letter by Foster, van der Molen and de Jong-van den Berg
Pasi Lampela, Sirpa Hartikainen, Raimo Sulkava and Risto Huupponen